Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PNT001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : As PNT001 is a humanized version of this antibody, this study provides further evidence for the ability of PNT001 to treat the cognitive impairments seen in tauopathies like Alzheimer’s disease and other neurodegenerative disorders.
Brand Name : PNT001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2021
Lead Product(s) : PNT001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PNT001
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Advanced Technology International
Deal Size : Undisclosed
Deal Type : Funding
Details : Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease.
Brand Name : PNT001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : PNT001
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Advanced Technology International
Deal Size : Undisclosed
Deal Type : Funding
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
Details : PNT001 is a monoclonal antibody targeting an epitope on a highly neurotoxic conformation of the tau protein called cis-pT231 tau. According to the data, PNT001 was demonstrated to be well-tolerated in healthy volunteers.
Brand Name : PNT001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 01, 2021
LOOKING FOR A SUPPLIER?